Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antimicrobial lozenge showed no clear difference in xerostomia compared with placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antimicrobial lozenge led to higher nausea (adverse effect) compared with placebo; GRADE not reported.
1 finding from 1 review
Quality of life and other oral related symptoms · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Insufficient evidence of a difference for global quality of life, mouth pain RR 0.94 (95% CI 0.66 to 1.33), sore/burning mouth RR 0.95 (95% CI 0.68 to 1.35), throat pain RR 0.79 (95% CI 0.56 to 1.12) (Duncan 2005)
1 study
GRADE not reported
Side effects (other: dryness in mouth, diarrhoea, constipation) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Mean VAS pain per day · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) showed no clear difference in mean VAS pain per day compared with placebo; GRADE not reported.
1 finding from 1 review
Total number of new ulcers over 90 days · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) led to lower total number of new ulcers over 90 days compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Number of ulcers at end of 90-day treatment · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) showed no clear difference in number of ulcers at end of 90-day treatment compared with placebo; GRADE not reported.
1 finding from 1 review
Average number of new lesions per week · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) led to lower number of new lesions per day compared with placebo; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Kerr 2010 (crossover, high risk of bias): no difference in oral dryness between active and placebo disks; increase in subjective oral moistness with both, persisting up to 2 weeks after last use (likely carryover);…
1 study
GRADE not reported
Salivary flow rate · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review